Hirashima N
Dept. of Gastroenterology, Chukyo Hospital.
Gan To Kagaku Ryoho. 1998 Feb;25 Suppl 1:125-32.
Patients with unresectable hepatocellular carcinoma (hepatoma) with hypervascularity were treated by SMANCS-TAE, which was performed by a superselective catheterization technique to inject gelatin sponge particles after administration of SMANCS. In 24 of 30 (80%) patients of first hepatoma treated by SMANCS-TAE, Grade 4 was obtained after about 1.5 (1-3) courses. The 2-year survival rate was 33%. SMANCS-TAE appears to have the same potential and safety as Lipiodol-TAE, treated selectively. Moreover, we can reduce the course of treatment and obtain good QOL of hepatoma patients except in advanced cases (vp 3 or T 4).
对无法切除的伴有血管增多的肝细胞癌（肝癌）患者采用丝裂霉素超液化碘油化疗栓塞术（SMANCS-TAE）进行治疗，该方法通过超选择性导管插入技术在给予丝裂霉素后注入明胶海绵颗粒。在接受SMANCS-TAE治疗的30例原发性肝癌患者中，24例（80%）在约1.5（1 - 3）个疗程后达到4级疗效。2年生存率为33%。SMANCS-TAE似乎与选择性治疗的碘油化疗栓塞术（Lipiodol-TAE）具有相同的潜力和安全性。此外，除晚期病例（vp 3或T 4）外，我们可以减少治疗疗程并提高肝癌患者的生活质量。
